These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 19736307

  • 1. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
    Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J, Monzo M.
    Carcinogenesis; 2009 Nov; 30(11):1903-9. PubMed ID: 19736307
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
    Patnaik SK, Kannisto E, Knudsen S, Yendamuri S.
    Cancer Res; 2010 Jan 01; 70(1):36-45. PubMed ID: 20028859
    [Abstract] [Full Text] [Related]

  • 3. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.
    Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y.
    Biomed Pharmacother; 2010 Jul 01; 64(6):399-408. PubMed ID: 20363096
    [Abstract] [Full Text] [Related]

  • 4. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer.
    Navarro A, Diaz T, Gallardo E, Viñolas N, Marrades RM, Gel B, Campayo M, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J, Monzo M.
    J Surg Oncol; 2011 Apr 01; 103(5):411-5. PubMed ID: 21400525
    [Abstract] [Full Text] [Related]

  • 5. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.
    Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK, Khuri FR.
    J Clin Oncol; 2004 Nov 15; 22(22):4575-83. PubMed ID: 15542809
    [Abstract] [Full Text] [Related]

  • 6. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM, Praeuer HW, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher AH, Roth JA.
    Br J Cancer; 2000 Aug 15; 83(4):473-9. PubMed ID: 10945494
    [Abstract] [Full Text] [Related]

  • 7. Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer.
    Campayo M, Navarro A, Viñolas N, Diaz T, Tejero R, Gimferrer JM, Molins L, Cabanas ML, Ramirez J, Monzo M, Marrades R.
    Eur Respir J; 2013 May 15; 41(5):1172-8. PubMed ID: 22835608
    [Abstract] [Full Text] [Related]

  • 8. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T.
    Lung Cancer; 2007 Oct 15; 58(1):131-8. PubMed ID: 17606310
    [Abstract] [Full Text] [Related]

  • 9. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.
    Lung Cancer; 2009 Mar 15; 63(3):410-7. PubMed ID: 18620780
    [Abstract] [Full Text] [Related]

  • 10. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, Morita M, Yasumoto K.
    Cancer; 2006 May 15; 106(10):2190-9. PubMed ID: 16598757
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.
    Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M.
    J Clin Oncol; 2009 Apr 20; 27(12):2030-7. PubMed ID: 19273703
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer.
    Wang ZX, Bian HB, Wang JR, Cheng ZX, Wang KM, De W.
    J Surg Oncol; 2011 Dec 20; 104(7):847-51. PubMed ID: 21721011
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer.
    Tan DF, Li Q, Rammath N, Beck A, Wiseman S, Anderson T, al-Salameh A, Brooks J, Bepler G.
    Anticancer Res; 2003 Dec 20; 23(2C):1665-72. PubMed ID: 12820438
    [Abstract] [Full Text] [Related]

  • 14. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.
    Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY.
    Cancer Res; 2007 Sep 15; 67(18):8433-8. PubMed ID: 17823410
    [Abstract] [Full Text] [Related]

  • 15. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer.
    Võsa U, Vooder T, Kolde R, Fischer K, Välk K, Tõnisson N, Roosipuu R, Vilo J, Metspalu A, Annilo T.
    Genes Chromosomes Cancer; 2011 Oct 15; 50(10):812-22. PubMed ID: 21748820
    [Abstract] [Full Text] [Related]

  • 16. The miR-34 family in cancer and apoptosis.
    Hermeking H.
    Cell Death Differ; 2010 Feb 15; 17(2):193-9. PubMed ID: 19461653
    [Abstract] [Full Text] [Related]

  • 17. Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer.
    Jung CK, Jung JH, Park GS, Lee A, Kang CS, Lee KY.
    Pathol Int; 2006 Sep 15; 56(9):503-9. PubMed ID: 16930330
    [Abstract] [Full Text] [Related]

  • 18. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting.
    Wu DW, Cheng YW, Wang J, Chen CY, Lee H.
    Cancer Res; 2010 Dec 15; 70(24):10392-401. PubMed ID: 21159652
    [Abstract] [Full Text] [Related]

  • 19. Reduced levels of miR-34a in neuroblastoma are not caused by mutations in the TP53 binding site.
    Feinberg-Gorenshtein G, Avigad S, Jeison M, Halevy-Berco G, Mardoukh J, Luria D, Ash S, Steinberg R, Weizman A, Yaniv I.
    Genes Chromosomes Cancer; 2009 Jul 15; 48(7):539-43. PubMed ID: 19373781
    [Abstract] [Full Text] [Related]

  • 20. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
    Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L.
    Cancer Res; 2009 Jul 15; 69(14):5761-7. PubMed ID: 19584283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.